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ABSTRACT
Objective To examine trends in long term survival in
patients alive 28 days after myocardial infarction and the
impact of evidence based medical treatments and
coronary revascularisation during or near the event.
Design Population based cohort with 12 year follow-up.
Setting Perth, Australia.
Participants 4451 consecutive patients with a definite
acutemyocardialinfarctionaccordingtotheWorldHealth
Organization MONICA (monitoring trends and
determinantsin cardiovascular disease) criteriaadmitted
to hospital during 1984-7, 1988-90, and 1991-3.
Main outcome measures All cause mortality identified
from official mortality records and the hospital morbidity
data, with death from cardiovascular disease as a
secondary end point.
Results In the 1991-3 cohort, 28 day survivors of acute
myocardial infarction had a 7.6% absolute event
reduction (95% confidence interval 4% to 11%) or a 28%
lowerrelativeriskreduction(16%to38%),unadjustedfor
risk of death, over 12 years after the incident admission
comparedwiththe1984-7cohort,similartothesurvivalof
the1988-90 cohort.The improvedsurvivalforthe 1991-3
cohort persisted after adjustment for demographic
factors, coronary risk factors, severity of disease, and
event complications with an adjusted relative risk
reductionof26%(14%to37%),butthiswasnotapparent
afterfurtheradjustmentformedicaltreatmentsinhospital
and coronary revascularisation procedures within
12 months of the incident myocardial infarction.
ConclusionTheimprovingtrendsin12yearsurvivalaftera
definite acute myocardial infarction are associated with
progressive use of evidence based treatments during the
initialadmissiontohospitalandinthe12monthsafterthe
event. These changes in the management of acute
myocardial infarction are probably contributing to the
continuing decline in mortality from coronary heart
disease in Australia.
INTRODUCTION
The continuing long term decline in mortality from
coronary heart disease in Australia and elsewhere has
been widely attributed to both declining incidence and
advances in medical treatment.
12 Previous studies in
Perth,includingtheWorldHealthOrganizationMON-
ICA project (monitoring trends and determinants in
cardiovascular disease),haveshown rapid andprogres-
sive uptake in aspects of medical care shown in
randomised clinical trials to reduce both acute and
medium term mortality after acute myocardial
infarction.
3-5 Such treatment included antiplatelet ther-
apy, thrombolysis, β blockers, lipid lowering drugs,
angiotensin converting enzyme inhibitors, and coron-
ary artery revascularisation (percutaneous coronary
interventionandcoronaryarterybypassgraft).
6-10There
are, however, few studies documenting the long term
impact at the population level on survival after acute
myocardial infarction or on death rates from coronary
heart disease. Such data could be used to support
policies promoting the systematic application of evi-
dencebasedmedicineincoronaryheartdiseasesuchas
thenationalserviceframeworkbenchmarkof“improv-
ing the use of effective medicines after heart attack
(especially use of aspirin, beta-blockers and statins) so
that 80-90% of people discharged from hospital follow-
ing a heart attack will be prescribed these drugs.”
11
We examined trendsin long term survival in people
registered as having an acute myocardial infarction
over a 10 year period in Australia.
METHODS
Study population
The study population comprised all residents of the
PerthStatisticalDivision(populationsize1.19millionin
1991) aged 35-64 who were admitted to hospital with a
first non-fatal definite acute myocardial infarction and
registered by the Perth MONICA project during 1984-
93.
12Fulldetailsoftheprojectaredescribedelsewhere.
3
Briefly,acutemyocardialinfarctionwasdiagnosedwith
MONICAcriteriabasedonsymptoms,cardiacenzyme
activity, and Minnesota coding of serial electrocardio-
grams. Only individuals who survived 28 days after an
incident acute myocardial infarction were included.
Incident events were defined as the absence of a
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hospitalrecordoftheindexeventandtheabsenceofan
admissiontohospitalforischaemicheartdisease(ICD-9
(international classification of diseases, ninth revision)
codes 410-414 and related conditions such as cardiac
dysrhythmias and heart failure, codes 427-429) in the
previousfouryears(theWesternAustraliandatalinkage
system includes all admissions to hospitals in Western
Australiasince1980).Wehavepreviouslyshownthata
negligible proportion of patients with recognised acute
myocardial infarction in Perth are managed solely at
home.
13
Data sources and record linkage
We linked the records of all people included in the
Perth MONICA register to a file of all hospital
admissions for cardiovascular disease and related
deaths in Western Australia from 1980-2005 using
standard linkage procedures developed by the data
linkage unit in the Department of Health of Western
Australia. From this we selected the subset of records
for the cases described above together with records of
allhospitaladmissionsforcardiovasculardiseasesince
1980 or death records (from any cause) to the end of
2005. From this we identified “incident” cases (no
admissionsforischaemicheartdiseaseinthefouryears
beforetheindexadmission);casesin whichthepatient
underwent coronary artery revascularisation proce-
dure within one year of the index event; and all deaths
(including date and coded cause of death) in the study
cohort up to the end of 2005, representing a minimum
follow-upperiodof12years.Casesofacutemyocardial
infarction, coronary artery revascularisation, and
cardiovascular death were identified and coded
according to the ICD-9 for 1984-7, ICD-9 clinical
modification from 1988 to 30 June 1999 (with the
Australian version being used from 1 July 1995 to 30
June 1999), and ICD-10 (Australian modified) for 1
July 1999 to 2005. These included acute myocardial
infarction (ICD-9 code 410 or ICD-10 code I21, I22);
percutaneous coronary intervention (codes 5-363,
36.01, 36.02, 36.05, or blocks 670, 35304-00, 35305-
00), percutaneous coronary intervention with stents
(codes 36.06, 36.07, or blocks 35310-00, 35310-01,
35310-02), coronary artery bypass graft (codes 5-361,
36.10-36.19, or blocks 672-679), or cardiovascular
death (codes 390-459 or I00-199). Several previous
studies have confirmed the validity of the Western
Australian data linkage system,
14-16 including the
official mortality records for Western Australia.
17
Follow-up and end points
Our principal end point was all cause mortality
identified from the death registry and the hospital
morbidity data collection, with death from cardio-
vascular disease as a secondary end point. In addition
we examined the incidence of coronary artery revas-
cularisation within a year of an index event as a
covariate relating to survival after one year.
Possible factors influencing long survival after acute
myocardial infarction
To assess the relation between calendar period and
survival after infarct we divided the cohort into three
Table 1 |Baseline characteristics (percentages of patients unless specified) in 28 day survivors
of an acute myocardial infarction (AMI): Perth MONICA cohort 1984-93
Characteristics
1984-7
(n=1745 )
1988-90
(n=1395 )
1991-3
(n=1311) P value
Age (years):
Mean (SD) 54 (7) 54 (7) 54 (7)
35-44 11 (192) 11 (160) 13 (177)
0.21 45-54 31 (537) 32 (451) 31 (412)
55-64 58 (1016) 56 (784) 55 (722)
Male 83 (1447) 81 (1130) 83 (1089) 0.28
Medical history:
Diabetes 8 (141) 9 (132) 11 (148) <0.01
Hypertension 40 (700) 40 (566) 38 (503) 0.49
Smoker past 12 months 55 (963) 49 (686) 49 (638) <0.003
AMI features:
Q wave AMI 56 (977) 51 (717) 47 (621) <0.001
Anterior AMI 43 (750) 47 (661) 47 (623) 0.03
≥0.5 mV ST deviation 63 (1092) 57 (792) 56 (729) <0.001
Electrocardiogram PREDICT score*:
0 24 (426) 33 (468) 31 (414)
<0.001
1 68 (1189) 61 (855) 63 (824)
2 4 (70) 3 (46) 3 (45)
3 3 (60) 2 (26) 2 (28)
Acute markers:
Median of CK ratio† (IQR) 7 (4-11) 6 (3-12) 6 (3-13) 0.20
Systolic blood pressure <100 mm Hg 4 (71) 4 (58) 5 (69) 0.28
Tachycardia >100 beats per min 27 (475) 27 (375) 28 (367) 0.60
Length of stay >10 days 2 1 1 0.10
Mean (SD) total days in hospital 3.5 (2.0) 2.6 (1.7) 3.0 (1.6) <0.001
Heart failure within 28 days of AMI 30 (523) 25 (353) 25 (330) 0.002
Cardiogenic shock within 28 days of AMI 3 (57) 2 (33) 3 (35) 0.29
Percutaneous coronary intervention:
0-28 days after incident AMI 0 (0) 8 (114) 11 (145)
<0.001 29-365 days 1 (12) 7 (93) 9 (123)
>1-12 years 6 (113) 7 (96) 9 (119)
Coronary artery bypass graft (CABG) surgery:
≤1 year after incident AMI 1 (23) 16 (219) 17 (227)
<0.001
>1-12 years 17 (304) 14 (201) 12 (162)
Any coronary revascularisation:
≤1 year after incident AMI 2 (35) 31 (426) 38 (495)
0.001
>1-12 years 24 (417) 21 (297) 21 (281)
Medical treatment in hospital:
Thrombolytic treatment 12 (218) 37 (519) 49 (644) <0.001
Antiplatelets 45 (785) 91 (1271) 97 (1273) <0.001
β blockers 66 (1148) 82 (1148) 88 (1150) <0.001
ACE inhibitors 9 (160) 15 (211) 29 (383) <0.001
Medical treatment at discharge:
Antiplatelets 32 (565) 81 (1130) 85 (1114) <0.001
ACE inhibitors 5 (91) 10 (146) 26 (339) <0.001
β blockers 55 (963) 70 (978) 77 (1015) <0.001
Lipid lowering drugs 2 (30) 3 (38) 5 (71) <0.001
Note: numbers might not add up exactly because of rounding. IQR=interquartile range; AMI=definite acute
myocardial infarction (MONICA criteria)
12;A C E =angiotensin converting enzyme; CK=creatine kinase.
* Predicting risk of death in cardiac disease tool score (score 0-3 based on ischaemic ECG progression).
14
†Defined as ratio of maximum CK value for event to relevant upper limit of normal.
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sufficient numbers in each group for comparison.
Other factors selected for analysis included age and
sex, smoking status (within the 12 months before the
admission), medical history as recorded in hospital
records (diabetes, history of hypertension), and mea-
sures of disease severity. These included creatine
kinase ratio (defined as the ratio of maximum creatine
kinasevaluefortheeventtotherelevantupperlimitof
normal for each hospital), abnormal ST segment
deviation (≥0.5 mV elevation or depression, or both),
electrocardiogram score with the predicting risk of
death in cardiac disease tool (score 0-3 based on
ischaemicelectrocardiogramprogression
18),andevent
complications (heart failure, cardiogenic shock, tachy-
cardia >100 beats/minute, systolic blood pressure
<100 mm Hg). Measures of treatment were identified
from randomised control trials for their efficacy in
managing acute myocardial infarction and from the
final MONICA treatment score.
1 These included
selected drugs used during the acute event or
prescribed at discharge or coronary artery revascular-
isation within 12 months.
Analysis of data
We examined differences in the distribution of demo-
graphic and clinical characteristics of those surviving
28 days after the incident acute myocardial infarction
for the three subcohorts (1984-7, 1988-90, 1991-3)
using χ
2 tests for categorical variables and t tests for
continuous variables. Where data for baseline vari-
ablesweremissingweimputednullvalues.Weplotted
Kaplan Meier curves of time to death for each of the
three subcohorts and used the log rank test to
determine if there were any statistical differences in
survival. We used Cox regression to examine the
hazard ratio for death over 12 months and 12 years,
with a stepwiseadjustmentfor possiblefactorsinfluen-
cing survival. All analyses were conducted using SPSS
version 15.0 and SAS version 9.1.
RESULTS
Baseline characteristics
From1984to1993,5340peopleaged35-64yearswho
were living in the Perth statistical division were
admitted to hospital with first ever definite acute
myocardial infarction and survived at least 28 days.
Some 889 (16%) were excluded for having been
admitted to hospital with other manifestations of
ischaemic heart disease within four years of the index
event. Table 1 shows the demographic and clinical
characteristics of the 4451 people, stratified according
to the three subcohorts. There was no significant
difference in the proportion of people in each 10 year
age group for the three subcohorts, with a combined
mean age of 54.4 (SD 7.3) years. Overall, 18% were
women, 10% had a history of diabetes, 51% were
current smokers, and 40% had a history of hyperten-
sion. The prevalence of diabetes increased with each
successive subcohort, smoking decreased, and hyper-
tension (treated and untreated) was unchanged. While
the median creatine kinase ratio was unchanged over
time, the prognostic markers of Q wave acute myo-
cardial infarction and ST deviation successively fell
with each subcohort. This was associated with com-
plementary changes in the electrocardiogram score
withthepredictingriskofdeathincardiacdiseasetool,
withthemostnoticeabledifferenceoccurringin1984-7
and between subsequent subcohorts. Likewise, the
proportion with changes on anterior electrocardio-
gram increased after the first subcohort with a parallel
reduction in the proportionof cases who had evidence
of heart failure within 28 days of the acute myocardial
infarction. Temporal changesin the remaining clinical
characteristics were not significant. There were, how-
ever, significant changes in treatment with each
successive subcohort: a marked increase in the use of
β blockers, antiplatelets, and thrombolytic treatment
during the acute episode, and significant uptake of
antiplatelets, angiotensin converting enzyme inhibi-
tors, β blockers, and lipid lowering drugs at the time of
dischargefromhospital(table1).Aschangesindrugsat
discharge ran parallel to changes in drugs in hospital it
is therefore not easy to distinguish between the effects
of acute treatment or subsequent long term treatment.
Trends in revascularisation
With each successive subcohort, more survivors of
acute myocardial infarction underwent coronary
artery revascularisation, particularly within
12 months.The proportion of revascularisation within
12monthswas2%in1984-7,31%in1988-90,and38%
in 1991-3 (P<0.001 for trend). Surgical revascularisa-
tioninthe12yearsoffollow-upwashighestinthe1984-
7 subcohort, whereas percutaneous coronary inter-
vention was highest during the first 12 months (and
28 days) in the 1991-3 subcohort. While the frequency
of coronary artery bypass graft was more than twice
thatofpercutaneouscoronaryinterventioninthe1984-
7 subcohort, by 1991-3 equal proportions of coronary
artery bypass graft and percutaneous coronary inter-
vention procedures (29% each) were performed. In
1984-7, 1988-90, and 1991-3 the proportions of each
subcohort undergoing coronary artery revascularisa-
tion were 26%, 52%, and 59%, respectively.
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Fig 1 | Kaplan-Meier all cause mortality in 28 day survivors of
acute myocardial infarction: Perth MONICA cohort 1984-93
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WeusedCoxregressionmodelstocomparetheriskof
deathforthreesubcohortsover12monthsand12years
with stepwise adjustment for possible factors influen-
cing survival. Table 2 shows adjusted hazard ratios for
death, adjusted for age, sex, and subcohort, associated
with individual factors thought to influence survival in
people alive a year after an incident acute myocardial
infarction and followed up for 12 years. Having a
history of diabetes or hypertension, being a current
smoker, and having a higher electrocardiogram score
with predicting risk of death in cardiac disease tool
wereallassociatedwithasignificantlyincreasedriskof
death.Survivalwasalsolowerinpatientswithevidence
of heart failure or cardiogenic shock within 28 days of
the acute myocardial infarction or tachycardia,
whereas a systolic blood pressure of <100 mm Hg on
presentationhadnoapparenteffectontheriskofdeath.
Similarly, interventions associated with a significantly
lowerriskofdeathover12yearsincludedatleasttwoof
the drug treatments in hospital (except possibly
angiotensin converting enzyme inhibitors), one or
two of the drugs prescribed at discharge (except
angiotensin converting enzyme inhibitors or lipid
lowering treatment when used alone), and coronary
revascularisation within 12 months of the incident
acutemyocardialinfarction.Note,thelowprescription
rates of angiotensin converting enzyme inhibitors and
lipid lowering drugs at discharge were associated with
an increased risk of death after 12 years, suggesting
confoundingbytheindicationforwhichthedrugswere
prescribed.
Trends in one year survival
In the 1991-3 subcohort, people surviving at least
28 days after an incident acute myocardial infarction
had a lower unadjusted all cause mortality at one year
compared with patients from the 1984-7 subcohort,
with a relative risk reduction of 40% (95% confidence
interval 10% to 60%) (table 3). The wide confidence
interval is the result of a smaller number of deaths
observed during one year follow-up. This survival
benefit persisted after adjustment for demographic
characteristics and coronary risk factors but was
reduced to 34% (0% to 56%) after further adjustment
forseverityofdiseaseandclinicalcomplications,andto
0( −65% to 39%) after further adjustment for medical
treatmentduringadmissiontohospital.Therewasnon-
significant improvement in survival over one year
between 1984-7 and 1988-90 subcohorts.
Trends in 12 year survival
Figures 1 and 2 and table 4 show survival analyses for
12 year all cause and cardiovascular mortality,
respectively. People in the 1991-3 subcohort alive at
one year after the incident event experienced a lower
unadjusted 12 year all cause mortality compared with
patients in the 1984-7 subcohort, with a relative risk
reduction of 28% (16% to 38%) (table 3), equivalent to
an absolute event reduction of 7.6% (4% to 11%)
(table 4). This difference in survival persisted after
adjustment for demographic variables, coronary risk
factors, severity of disease, and clinical complications,
with a relative risk reduction of 26% (14% to 37%), but
was no longer apparent after further adjustment for
medical treatment during admission and coronary
artery revascularisation within 12 months of the
incident acute myocardial infarction. The improve-
mentinsurvivalover12yearsbetweenthe1984-7and
1988-90 subcohorts was borderline (P=0.055). The
improvement in long term survival across the three
subcohortspersistedwhenweseparatelyanalyseddata
forthe3554menandafterananalysisincluding28day
survivors of acute myocardial infarction with a history
ofischaemicheartdisease(12yearcumulativesurvival
of 67.9%, 69.9%, and 74.1% for successive subcohorts,
respectively).
Table 2 |Adjusted* hazard ratios for death for individual factors at 12 years in one year
survivors of acute myocardial infarction (AMI): Perth MONICA cohort 1984-93
Hazard ratio (95% CI) P value
History of diabetes 2.49 (2.12 to 2.93) <0.001
History of hypertension 1.40 (1.24 to 1.58) <0.001
Current or recent smoker 1.31 (1.15 to 1.48) <0.001
ECG PREDICT score†
0 1.00 <0.001
1 1.43 (1.23 to 1.67) <0.001
2 2.71 (2.06 to 3.58) <0.001
3 2.48 (1.78 to 3.44)
Heart failure within 28 days of AMI 1.93 (1.70 to 2.18) <0.001
Cardiogenic shock within 28 days of AMI 1.90 (1.42 to 2.55) <0.001
Tachycardia >100 beats/minute 1.66 (1.46 to 1.89) <0.001
Systolic blood pressure <100 mm Hg 1.08 (0.84 to 1.40) 0.526
In hospital medical treatment for AMI:
Thrombolysis 0.74 (0.64 to 0.86) <0.001
Antiplatelet 0.77 (0.65 to 0.90) <0.001
β blocker 0.55 (0.48 to 0.63) <0.001
ACE inhibitor 1.91 (1.64 to 2.22) <0.001
Composite treatment score‡:
0 1.00 <0.001
1 0.84 (0.68 to 1.04) 0.118
2 0.70 (0.56 to 0.87) 0.001
3 0.56 (0.44 to 0.72) <0.001
4 0.69 (0.49 to 0.99) 0.043
Medical treatment on discharge after AMI:
β blockers 0.56 (0.50 to 0.64) <0.001
Antiplatelets 0.74 (0.64 to 0.85) <0.001
ACE inhibitors 2.23 (1.89 to 2.62) <0.001
Lipid lowering 1.40 (1.01 to 1.94) 0.041
Composite treatment score:
0 1.00 <0.001
1 0.69 (0.58 to 0.82) <0.001
2 0.58 (0.48 to 0.69) <0.001
3 0.84 (0.64 to 1.11) 0.224
4 0.97 (0.36 to 2.62) 0.950
Coronary artery revascularisation within 12 months of AMI 0.53 (0.44 to 0.64) <0.001
ACE=angiotensin converting enzyme; AMI=definite acute myocardial infarction (MONICA criteria).
12
*Adjusted for age, sex, and subcohort.
†Predicting risk of death in cardiac disease tool score (score 0-3 based on ischaemic ECG progression).
14
‡Composite treatment score (score 0-4 based on number of drug treatments used in each patient as listed in
table).
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by subcohort were comparable with findings for all
cause mortality (fig 2). The proportion of total deaths
after 12 years caused by cardiovascular disease in first,
second, and third subcohorts was 70%, 66%, and 61%,
respectively.
DISCUSSION
Thispopulationbasedstudyofthemetropolitanareaof
Perth, Western Australia, shows improving trends in
one and 12 year survival in those alive at least 28 days
afteradefiniteacutemyocardialinfarction.Previously,
28 day casefatality didnot differ forthe entirecohort.
3
Improved survival in the early 1990s over the early
1980s corresponds with the introduction of new
treatments rather than changes in risk factors before
the infarction or severity of infarction. The improve-
mentinthe1991-3subcohortcomparedwiththe1984-
7 and 1988-90 subcohorts was significant. The
differences in survival across the three subcohorts
persisted after adjustment for age, sex, and coronary
risk factors and were marginally different after further
adjustment for severity of disease and event complica-
tions. Once we adjusted for medical treatment,
however, the survival difference for the 1991-3
subcohort was even less apparent after one year, and
adjustment for both medical treatment and coronary
revascularisationwithin12monthsinthosealiveatone
year resulted in the differences between subcohorts in
survival to 12 years becoming non-significant.
Strengths and weaknesses of study
Our study documents changes in one and 12 year
survival in a population based cohort of people
admitted to hospital for acute myocardial infarction,
withstringentdiagnosticcriteria,overa10yearperiod
during which medical and surgical treatment for
coronary heart disease was changing rapidly in
response to published results of large randomised
controlledtrialandmeta-analyses.Weappliedunchan-
ging criteria for definite acute myocardial infarction
based on electrocardiography, cardiac biomarkers,
and symptoms as defined in the MONICA project,
12
which would overcome any diagnostic drift over time.
Local research has shown that robust evidence from
clinical trials for the treatment and management of
acute myocardial infarction was adopted quickly in
Perth.
3-519 Nearcompletefollow-up(estimatedat99%)
wasensuredthroughthewellestablishedproceduresof
the Western Australian data linkage system. Our
analysis also reconfirmed the main predictors of
Table 3 |Hazard ratios (95% confidence intervals) for death in survivors of an acute myocardial infarction (AMI) after stepwise
addition of risk markers: Perth MONICA cohort 1984-93
1988-90 v 1984-7 1991-3 v 1984-7
Death at one year in 28 day survivors
Unadjusted 0.77 (0.53 to 1.11) 0.60 (0.40 to 0.90)
Adjusted for:
Demographic factors (age and sex) 0.76 (0.53 to 1.11) 0.61 (0.40 to 0.91)
Above plus coronary risk factors* 0.76 (0.53 to 1.11) 0.60 (0.40 to 0.91)
Above plus disease severity† 0.82 (0.56 to 1.19) 0.64 (0.42 to 0.96)
Above plus clinical complications during admission‡ 0.83 (0.57 to 1.20) 0.66 (0.44 to 1.01)
Above plus medical treatment in hospital§ 1.10 (0.72 to 1.69) 1.00 (0.61 to 1.65)
Death at 12 years in one year survivors
Unadjusted 0.88 (0.76 to 1.02) 0.72 (0.62 to 0.84)
Adjusted for:
Demographic factors (age and sex) 0.88 (0.76 to 1.01) 0.72 (0.62 to 0.84)
Above plus coronary risk factors* 0.88 (0.76 to 1.01) 0.71 (0.61 to 0.82)
Above plus disease severity† 0.93 (0.80 to 1.07) 0.73 (0.63 to 0.85)
Above plus clinical complications during admission‡ 0.94 (0.82 to 1.09) 0.74 (0.63 to 0.86)
Above plus medical treatment in hospital§ 1.19 (1.00 to 1.40) 0.96 (0.79 to 1.16)
Above plus CAR within 12 months 1.38 (1.16 to 1.63) 1.15 (0.94 to 1.40)
CAR=coronary artery revascularisation.
*History of diabetes, history of hypertension, and current or recent smoker.
†Predicting risk of death in cardiac disease tool score (score 0-3 based on ischaemic ECG progression).
14
‡Heart failure, cardiogenic shock, tachycardia>100 beats/minute, systolic blood pressure <100 mm Hg within 28 days of admission to hospital.
§Thrombolysis, antiplatelet, β blocker, angiotensin converting enzyme inhibitor, and lipid lowering drugs.
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Fig 2 | Kaplan-Meier cardiovascular mortality in 28 day
survivors of acute myocardial infarction: Perth MONICA cohort
1984-93
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previous studies
2021 but over a longer term.
Theuseofprovedmedicaltreatment,asexemplified
by antiplatelets, thrombolysis, and β blockers during
admission to hospital, and performance of coronary
artery revascularisation within 12 months after an
incident acute myocardial infarction accounted for the
greatest improvement in survival over 12 years. In
practical terms, proportionately 9% fewer cardio-
vascular deaths occurred over 12 years in the 1991-3
subcohort than in the 1984-7 subcohort.
This study also has some limitations. Severity of
disease as measured by electrocardiography, peak
creatine kinase activity, and haemodynamic indices
did not account for differences in survival between the
subcohorts. More sophisticated measures such as
ejection fraction and indices of infarct size, as well as
information on delay between onset of symptoms and
arrival at hospital, which are not routinely available in
hospital records, might indicate a contribution of
altered severity to the change in longer term survival.
These data were not available for analysis.
We ascertained the history of diabetes mellitus,
hypertension, and smoking from the medical record
using clinical diagnoses, which could be subject to
reporting bias. Prospectively collected cross sectional
data from population based samples of Australians,
however, indicated trends in prevalence of diabetes,
hypertension, and smoking from 1980-99 that are
consistent with our data.
22
Although our findings involve a relatively younger
population(age35-64)theyareconsistentwithfindings
from an unrestricted cohort of adults in Scotland.
23
Also a recent study from Boston in elderly patients
found similar long term survival benefit.
24
Our study was observational and the results should
beinterpretedwithcaution.Observationalstudiesthat
attempt to evaluate the efficacy of different treatment
regimensmightintroducetreatmentselectionbiasand
competing recognition and management of
comorbidity.
2526 This type of bias is of less concern in
our study because we compared periods rather than
treatment groups. Despite having adjusted for con-
foundingwhenwehadrelevantdata,iftherewasabias
involving,say,physicianpreference,thatchangedover
the three periods, it would remain.
Relevance of our findings
Other studies have reported improvements in short
and long term survival after acute myocardial infarc-
tion during similar historical periods.
2327 In a study of
117718 patients admitted to hospital with a principal
diagnosis of acute myocardial infarction in Scotland
between 1986 and 1995, the crude case fatality at one
year fell from 35.3% to 27.8% and at five years from
52.3%in1986to49.3%in1991.
23Theimprovementin
short term survival was attributed to thrombolysis,
angiotensinconvertingenzymeinhibitors,andaspirin,
with the long term survival advantage linked to diet,
smoking cessation, and continuing treatment with
aspirin and β blockers.
27 Similar conclusions were
drawn from the population based Minnesota Heart
Survey, which showed ongoing declines in three year
case fatality after admission to hospital for acute
myocardial infarction in men and women aged <75
discharged from greater Minneapolis and St Paul
hospitals from 1985 to 1995
27 but not from 1980 to
1985.
2829 Furthermore, the Minnesota group con-
cluded that coronary artery revascularisation was
probably a significant contributor in improved
survival.
27 Goldberg et al showed a significant
improvement in one year survival, adjusted for age,
acute prognostic markers, and thrombolysis, among
patients with acute myocardial infarction discharged
from hospital during the early to mid-1990scompared
withthosedischargedinthepreviousdecade.
30Finally,
a registry study of residents with acute myocardial
infarction from Gerona, Spain, showed no significant
differencesinthethreeyearmortalityafterdischargeof
8.3%in28daysurvivorsbetweenperiods1978-85and
1986-8,
31 although the observational period in this
studyandtheearlierreportsfromtheMinnesotaHeart
Survey
2829 were before the widespread uptake of
thrombolytic treatment, antiplatelets, and coronary
artery revascularisation.
Inadditiontovariablesinpatients,improvementsin
long term survival are probably attributable to a
combination of various treatments rather than any
single treatment. Over the study period there was an
increasing use of relevant medical treatment and
coronary artery revascularisation at the onset of acute
myocardialinfarction,allofwhichhavebeenshownto
reduce cardiac mortality and morbidity in Western
Australia.
3-519 While we have no record of ongoing
Table 4 |Cumulative mortality (percentage and 95% confidence intervals) in 28 day survivors of acute myocardial infarction:
Perth MONICA cohort 1984-93
Aggregate year of diagnosis No of patients 1 year 5 year 10 years 12 years
Cumulative all cause mortality
1984-7 1745 4.2 (3.2 to 5.1) 13.1 (11.5 to 14.7) 25.1 (23.1 to 27.2) 29.9 (27.7 to 32.1)
1988-90 1395 3.2 (2.2 to 4.1) 11.9 (10.2 to 13.6) 21.6 (19.4 to 23.8) 26.4 (24.1 to 28.8)
1991-3 1311 2.5 (1.6 to 3.4) 8.9 (7.3 to 10.5) 17.1 (15.5 to 19.2) 22.3 (20.0 to 24.6)
Cumulative cardiovascular mortality
1984-7 1745 3.4 (2.6 to 4.3) 10.3 (8.8 to 11.7) 18.4 (16.6 to 20.2) 20.8 (18.9 to 22.8)
1988-90 1395 2.6 (1.8 to 3.5) 8.1 (6.6 to 9.5) 14.5 (12.7 to 16.4) 17.6 (15.6 to 19.5)
1991-3 1311 2.0 (1.3 to 2.8) 6.2 (4.9 to 7.6) 11.1 (9.4 to 12.7) 13.6 (11.8 to 15.5)
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discharge, Czarn et al showed relatively high levels of
compliance with such treatment in MONICA patients
with acute myocardial infarction during 1984-8 and
followed up for one to six years.
5 Furthermore, almost
half continued to see a specialist, while 65% saw a
general practitioner.
5
Subsidised statin treatment during MONICA enrol-
ment was available to those with a qualifying serum
cholesterol concentration ≥6.5 mmol/l, falling to
5.5 mmol/l in the 1990s. National data show that
prescriptions for lipid lowering drugs and angiotensin
converting enzyme inhibitors have increased nearly
20-foldfrom1991to2004.Thissuggeststhatpatientsin
the1991-3subcohortwereprobablyexposedtogreater
use of such drugs than those in the earlier subcohorts,
especially in the years of follow-up before 1993 when
almostcertainlymuchlowerprescriptionratesexisted.
Changes in lifestyle characteristics and dietary
practices might also have contributed to trends in
survival.
2232 We found a 3% increase in diabetes, and
corresponding population data show a mean upward
trend in body mass index of about an 0.8% annual rise
in the prevalence of overweight.
22 This is counter-
balanced by more modest reductions in physical
inactivity, mean total cholesterol concentration, and
smoking in the same population.
22 In our analysis we
havecontrolledforhypertensionanddiabetesmellitus
that are partly consequences of overweight and
lifestyle. Data on body mass index, physical inactivity,
and smoking, however, were not available and so
cannot directly be adjusted for.
Changes in severity of disease could also improve
long term survival after acute myocardial infarction,
though we found no change in creatine kinase ratios
associated with proportionally fewer ischaemic
changesonelectrocardiographyandalowerincidence
of heart failure from the 1984-7 to the 1991-3
subcohort. Adjustment for these markers of disease
severity did not alter the one and 12 year survival
differences seen between the 1991-3 and 1984-7
subcohorts. Furthermore, we used stringent and
unchanged diagnostic criteria throughout the study
period.MONICAdatafromthetwoAustraliancentres
havepreviouslyreportedlittledifferencein28daycase
fatality.
3 Our finding of unchanged severity of disease
accords with haemodynamic, cardiac enzyme, and
electrocardiographic findings in cases of validated
acute myocardial infarction registered by the Athero-
sclerosis Risk in Communities study from 1987 to
1994.
33 Continued community surveillance in Finland
of adults experiencing an acute myocardial infarction
from1980to2000hasalsoshownafallingaprevalence
of large Q waves and other ischaemic findings on
electrocardiography.
34
Conclusion
Oneand12yearsurvivalincreasedinpatientsaged35-
64 from Perth whowere alive 28 days after an incident
acute myocardial infarction from 1984 to 1993. The
improvement is associated with changes in treatment
duringand within12 monthsofthe event,exemplified
by antiplatelets, thrombolysis, β blockers, and coron-
ary artery revascularisation. These changes are con-
sistent with better treatment of acute myocardial
infarction having an important impact on the continu-
ing decline in mortality fromcoronary heart diseasein
Australia. The magnitude of the contribution of
evidence based treatment to the decline in mortality
from coronary heart disease remains unanswered as
does the contribution of chronic cardioproctective
pharmacotherapy.
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